ASRT Stock Forecast & Price Target

Assertio Holdings Inc. has demonstrated an impressive gross margin increase to 70% from 65% in the prior year quarter, attributable to reduced inventory write-downs and the completion of inventory step-up amortization for ROLVEDON. The company's positive outlook is further bolstered by anticipated sequential growth in ROLVEDON sales for the remainder of the year, indicating strong demand and effective market positioning. Additionally, as inventory write-down impacts diminish, gross margins are poised for gradual improvement, enhancing the overall financial stability of the company.

Assertio Holdings has experienced a decline in net product sales for its pharmaceutical products, with Indocin net sales dropping to $5.5 million in 1Q25 from $8.7 million in the previous quarter, primarily due to generic competition affecting both volume and pricing. Additionally, ROLVEDON's net sales fell to $13.1 million in 1Q25 from $14.5 million in 1Q24, driven by lower pricing despite a modest increase in volume. The company reported a net loss of $0.14 in 1Q25, contrasting sharply with previous optimistic projections of $63.9 million in profitability, indicating ongoing financial challenges.